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Background: Progressive supranuclear palsy (PSP) is a neuropathologically defined disease presenting with a broad spectrum of clinical phenotypes. 
Objective: To identify clinical features and investigations that predict or exclude PSP pathology during life, aiming at an optimization of the clinical diagnostic criteria for PSP.
Methods: We performed a systematic review of the literature published since 1996 to identify clinical features and investigations that may predict or exclude PSP pathology. We then extracted standardized data from clinical charts of patients with pathologically diagnosed PSP and relevant disease controls, and calculated sensitivity, specificity and positive predictive value of key clinical features for PSP in this cohort. 
Results: Of 4166 articles identified by an automated database inquiry, 269 met the predefined standards. The literature review identified clinical features predictive of PSP, including features of the 4 functional domains, i.e., “ocular motor dysfunction”, “postural instability”, “akinesia”, and “cognitive dysfunction”. No biomarker or genetic feature was found reliably validated to predict definite PSP.  
High-quality original natural history data were available from 206 patients with pathologically diagnosed PSP and from 231 pathologically diagnosed disease controls (54 corticobasal degeneration, 51 multiple system atrophy with predominant parkinsonism, 53 Parkinson`s disease, 73 behavioral variant frontotemporal dementia). We identified clinical features that predicted PSP pathology, including phenotypes other than Richardson’s syndrome, with varying sensitivity and specificity. 




Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disease, first described by JC Richardson and colleagues in 1964 HYPERLINK \l "_ENREF_1" \o "Steele, 1964 #347"  ADDIN EN.CITE <EndNote><Cite><Author>Steele</Author><Year>1964</Year><RecNum>347</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>347</rec-number><foreign-keys><key app="EN" db-id="wxrax9w07529swefspux0dz1psdvwvr0evwx" timestamp="1480241730">347</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Steele, J. C.</author><author>Richardson, J. C.</author><author>Olszewski, J.</author></authors></contributors><titles><title>Progressive Supranuclear Palsy. A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum with Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia</title><secondary-title>Arch Neurol</secondary-title></titles><periodical><full-title>Arch Neurol</full-title></periodical><pages>333-59</pages><volume>10</volume><keywords><keyword>*Basal Ganglia</keyword><keyword>*Brain Diseases</keyword><keyword>*Brain Stem</keyword><keyword>*Cerebellar Diseases</keyword><keyword>*Cerebellum</keyword><keyword>*Dementia</keyword><keyword>*Diagnosis, Differential</keyword><keyword>*Dystonia</keyword><keyword>*Ganglia</keyword><keyword>*Histology</keyword><keyword>Humans</keyword><keyword>*Mental Disorders</keyword><keyword>*Paralysis</keyword><keyword>*Pathology</keyword><keyword>*Pseudobulbar Palsy</keyword><keyword>*Pyramidal Tracts</keyword><keyword>*Supranuclear Palsy, Progressive</keyword><keyword>*Ganglia, basal</keyword></keywords><dates><year>1964</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>0003-9942 (Print)&#xD;0003-9942 (Linking)</isbn><accession-num>14107684</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/14107684</url></related-urls></urls></record></Cite></EndNote>1. Its prevalence was estimated from a clinical perspective to be 3-6/100.000 ADDIN EN.CITE ,. Age at symptom onset is 65 years and disease duration to death is 6-9 years, on average ADDIN EN.CITE ,. Neuropathological examination provides the gold standard for diagnosis, defining the disease entity ADDIN EN.CITE 5-7. The NINDS-SPSP (National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy) criteria for the clinical diagnosis of PSP HYPERLINK \l "_ENREF_7" \o "Litvan, 1996 #18"  ADDIN EN.CITE <EndNote><Cite><Author>Litvan</Author><Year>1996</Year><RecNum>18</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="wxrax9w07529swefspux0dz1psdvwvr0evwx" timestamp="1480186703">18</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Litvan, I.</author><author>Agid, Y.</author><author>Calne, D.</author><author>Campbell, G.</author><author>Dubois, B.</author><author>Duvoisin, R. C.</author><author>Goetz, C. G.</author><author>Golbe, L. I.</author><author>Grafman, J.</author><author>Growdon, J. H.</author><author>Hallett, M.</author><author>Jankovic, J.</author><author>Quinn, N. P.</author><author>Tolosa, E.</author><author>Zee, D. S.</author></authors></contributors><auth-address>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-9130, USA.</auth-address><titles><title>Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop</title><secondary-title>Neurology</secondary-title></titles><periodical><full-title>Neurology</full-title></periodical><pages>1-9</pages><volume>47</volume><number>1</number><keywords><keyword>Humans</keyword><keyword>Supranuclear Palsy, Progressive/*diagnosis</keyword></keywords><dates><year>1996</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>0028-3878 (Print)&#xD;0028-3878 (Linking)</isbn><accession-num>8710059</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/8710059</url></related-urls></urls></record></Cite></EndNote>7 are commonly applied as ante mortem diagnostic standard. A diagnosis of “probable” PSP requires the presence of vertical supranuclear gaze palsy plus postural instability and falls within the first year of symptoms. For a diagnosis of “possible” PSP, either vertical supranuclear gaze palsy or a combination of slow vertical saccades and postural instability with falls in the first year need to be present  HYPERLINK \l "_ENREF_7" \o "Litvan, 1996 #18"  ADDIN EN.CITE <EndNote><Cite><Author>Litvan</Author><Year>1996</Year><RecNum>18</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="wxrax9w07529swefspux0dz1psdvwvr0evwx" timestamp="1480186703">18</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Litvan, I.</author><author>Agid, Y.</author><author>Calne, D.</author><author>Campbell, G.</author><author>Dubois, B.</author><author>Duvoisin, R. C.</author><author>Goetz, C. G.</author><author>Golbe, L. I.</author><author>Grafman, J.</author><author>Growdon, J. H.</author><author>Hallett, M.</author><author>Jankovic, J.</author><author>Quinn, N. P.</author><author>Tolosa, E.</author><author>Zee, D. S.</author></authors></contributors><auth-address>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-9130, USA.</auth-address><titles><title>Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop</title><secondary-title>Neurology</secondary-title></titles><periodical><full-title>Neurology</full-title></periodical><pages>1-9</pages><volume>47</volume><number>1</number><keywords><keyword>Humans</keyword><keyword>Supranuclear Palsy, Progressive/*diagnosis</keyword></keywords><dates><year>1996</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>0028-3878 (Print)&#xD;0028-3878 (Linking)</isbn><accession-num>8710059</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/8710059</url></related-urls></urls></record></Cite></EndNote>7. This clinical manifestation of PSP with predominant ocular motor dysfunction and postural instability is called Richardson’s syndrome (PSP-RS). The NINDS-SPSP criteria have excellent specificity ADDIN EN.CITE ,  but low sensitivity early in the clinical course ADDIN EN.CITE 9-12 because typical features of PSP-RS are either absent or become apparent only after several years in a significant proportion of PSP patients ADDIN EN.CITE ,,,. A recent analysis of autopsy-confirmed patients suggested that 60-75% of patients with ascertained PSP pathology have variant PSP syndromes (vPSP) other than PSP-RS ADDIN EN.CITE 4. Too often, patients with vPSP, but also with PSP-RS, are diagnosed only after several years or never during lifetime ADDIN EN.CITE 4. However, early diagnosis is urgently warranted, since disease-modifying treatments are being developed, and would ideally be initiated before relevant cognitive or motor impairment is present ADDIN EN.CITE ,. 




The MDS-PSPSG steering committee (GUH, ALB, IL, LIG, MS) assembled working groups of key experts to conduct a systematic review of published literature on specific aspects relevant to the diagnosis of PSP. Members of the groups defined key questions (Table 1) and search terms (Supplemental Table 1). Literature was searched on PubMed, Cochrane, Medline, and PSYCInfo databases for entries from 1996 until 2015, using search terms for each key question and for PSP (‘‘Progressive Supranuclear Palsy” OR ‘‘Progressive Supranuclear Ophthalmoplegia’’ OR ‘‘Steele Richardson Olszewski syndrome’’). Study group members were encouraged to add relevant articles for consideration throughout the project period (end of 2016), particularly those published after 2015. All titles and abstracts of identified articles were reviewed independently by 2 investigators (GH, CK) to select research articles, systematic reviews and meta-analyses, published in English using either a postmortem diagnosis or the highly specific NINDS-SPSP criteria as diagnostic standard. Three independent members of the consortium (GUH, GR, CK) analyzed the methodology (internal validity, overall assessment, description) of these articles using the checklist of the Scottish Intercollegiate Guidelines Network (SIGN, www.sign.ac.uk (​http:​/​​/​www.sign.ac.uk​)) HYPERLINK \l "_ENREF_37" \o ", 2008 #1120"  ADDIN EN.CITE <EndNote><Cite><Year>2008</Year><RecNum>1120</RecNum><DisplayText><style face="superscript">37</style></DisplayText><record><rec-number>1120</rec-number><foreign-keys><key app="EN" db-id="wxrax9w07529swefspux0dz1psdvwvr0evwx" timestamp="1483988285">1120</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors></contributors><titles><title>SIGN 50: a guideline developers’ handbook</title></titles><dates><year>2008</year></dates><pub-location>Edinburgh</pub-location><publisher>Scottish Intercollegiate Guidelines Network</publisher><urls></urls></record></Cite></EndNote>37 and rated their methodological quality as “very reliable”, “OK”, or “insufficient”. “Insufficient” articles were excluded from further analysis. For each included article, 2 independent experts collated standardized information on 1) study design, 2) evidence level, 3) patient characteristics, 4) key test or feature, 5) key findings, and 6) diagnostic value. These written summaries were provided to all MDS-PSPSG members. Evidence was then summarized for each key question by the working groups (Supplemental Table 1). 

Clinico-pathological case series
This work was approved by the ethics committee of the Technical University of Munich and the participating centers. Autopsied cases with detailed clinical information and a definite diagnosis of PSP ADDIN EN.CITE ,,, CBD ADDIN EN.CITE ,, MSA-P HYPERLINK \l "_ENREF_40" \o "Trojanowski, 2007 #924"  ADDIN EN.CITE <EndNote><Cite><Author>Trojanowski</Author><Year>2007</Year><RecNum>924</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>924</rec-number><foreign-keys><key app="EN" db-id="wxrax9w07529swefspux0dz1psdvwvr0evwx" timestamp="1481218415">924</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Trojanowski, J. Q.</author><author>Revesz, T.</author><author>Neuropathology Working Group on, M. S. A.</author></authors></contributors><auth-address>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Ageing of the University of Pennsylvania, Philadelphia, PA 19104-4283, USA. trojanow@mail.med.upenn.edu</auth-address><titles><title>Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy</title><secondary-title>Neuropathol Appl Neurobiol</secondary-title></titles><periodical><full-title>Neuropathol Appl Neurobiol</full-title></periodical><pages>615-20</pages><volume>33</volume><number>6</number><keywords><keyword>Autopsy</keyword><keyword>Brain/*pathology</keyword><keyword>Humans</keyword><keyword>Multiple System Atrophy/*diagnosis</keyword></keywords><dates><year>2007</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>0305-1846 (Print)&#xD;0305-1846 (Linking)</isbn><accession-num>17990994</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/17990994</url></related-urls></urls><electronic-resource-num>10.1111/j.1365-2990.2007.00907.x</electronic-resource-num></record></Cite></EndNote>40, PD HYPERLINK \l "_ENREF_41" \o "Dickson, 2009 #915"  ADDIN EN.CITE <EndNote><Cite><Author>Dickson</Author><Year>2009</Year><RecNum>915</RecNum><DisplayText><style face="superscript">41</style></DisplayText><record><rec-number>915</rec-number><foreign-keys><key app="EN" db-id="wxrax9w07529swefspux0dz1psdvwvr0evwx" timestamp="1481218063">915</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dickson, D. W.</author><author>Braak, H.</author><author>Duda, J. E.</author><author>Duyckaerts, C.</author><author>Gasser, T.</author><author>Halliday, G. M.</author><author>Hardy, J.</author><author>Leverenz, J. B.</author><author>Del Tredici, K.</author><author>Wszolek, Z. K.</author><author>Litvan, I.</author></authors></contributors><auth-address>Mayo Clinic, Jacksonville, FL, USA.</auth-address><titles><title>Neuropathological assessment of Parkinson&apos;s disease: refining the diagnostic criteria</title><secondary-title>Lancet Neurol</secondary-title></titles><periodical><full-title>Lancet Neurol</full-title></periodical><pages>1150-7</pages><volume>8</volume><number>12</number><keywords><keyword>Humans</keyword><keyword>Lewy Bodies/pathology</keyword><keyword>Parkinson Disease/*diagnosis/genetics/*pathology</keyword><keyword>alpha-Synuclein/genetics</keyword></keywords><dates><year>2009</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1474-4465 (Electronic)&#xD;1474-4422 (Linking)</isbn><accession-num>19909913</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/19909913</url></related-urls></urls><electronic-resource-num>10.1016/S1474-4422(09)70238-8</electronic-resource-num></record></Cite></EndNote>41, and a clinical syndrome of bvFTD ADDIN EN.CITE 42 with FTLD from any underlying non-PSP/CBD proteinopathy (i.e. FTLD-Tau including FTDP-17 or Pick’s disease, FTLD-TDP or FTLD-FUS) HYPERLINK \l "_ENREF_43" \o "Neary, 1998 #929"  ADDIN EN.CITE <EndNote><Cite><Author>Neary</Author><Year>1998</Year><RecNum>929</RecNum><DisplayText><style face="superscript">43</style></DisplayText><record><rec-number>929</rec-number><foreign-keys><key app="EN" db-id="wxrax9w07529swefspux0dz1psdvwvr0evwx" timestamp="1481218807">929</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Neary, D.</author><author>Snowden, J. S.</author><author>Gustafson, L.</author><author>Passant, U.</author><author>Stuss, D.</author><author>Black, S.</author><author>Freedman, M.</author><author>Kertesz, A.</author><author>Robert, P. H.</author><author>Albert, M.</author><author>Boone, K.</author><author>Miller, B. L.</author><author>Cummings, J.</author><author>Benson, D. F.</author></authors></contributors><auth-address>Manchester Royal Infirmary, UK.</auth-address><titles><title>Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria</title><secondary-title>Neurology</secondary-title></titles><periodical><full-title>Neurology</full-title></periodical><pages>1546-54</pages><volume>51</volume><number>6</number><keywords><keyword>Dementia/*diagnosis/*pathology</keyword><keyword>Frontal Lobe/*pathology</keyword><keyword>Humans</keyword><keyword>Temporal Lobe/*pathology</keyword></keywords><dates><year>1998</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>0028-3878 (Print)&#xD;0028-3878 (Linking)</isbn><accession-num>9855500</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/9855500</url></related-urls></urls></record></Cite></EndNote>43 were recruited from 9 brain banks with expertise in neurodegenerative diseases (Ludwig-Maximilians-University, Munich, Germany; University Hospital of Bordeaux, France; King’s College, London, UK; University of Lund, Lund, Sweden; Erasmus Medical Center, Rotterdam, Netherlands; Hospital Clinic–IDIBAPS, Barcelona, Spain; University of Saskatchewan, Canada; Johns Hopkins University, Baltimore, USA; University of Pennsylvania, Philadelphia, USA). Before death, all donors had given written informed consent according to the Declaration of Helsinki for the scientific use of their brains and medical records. While cases with minor age-related co-pathology (e.g., amyloid-beta pathology, argyrophilic grains) were included in the analysis, cases with more than one pathological diagnosis were excluded. Clinical data were acquired as described previously ADDIN EN.CITE 4. In short, demographic data, age at disease onset and death, disease duration, initial clinical diagnosis, final clinical diagnosis, and 37 clinical features (Supplemental Table 2) including year of their onset were abstracted from clinical records using a standardized template by local physicians. Features not specifically mentioned in the records were considered absent. 

Statistics




Two key questions on radiological biomarkers of PSP are reported in detail in an accompanying paper in this issue of Movement Disorders HYPERLINK \l "_ENREF_44" \o "Whitwell, submitted #1121"  ADDIN EN.CITE <EndNote><Cite><Author>Whitwell</Author><Year>submitted</Year><RecNum>1121</RecNum><DisplayText><style face="superscript">44</style></DisplayText><record><rec-number>1121</rec-number><foreign-keys><key app="EN" db-id="wxrax9w07529swefspux0dz1psdvwvr0evwx" timestamp="1483988833">1121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Whitwell</author></authors></contributors><titles><title>Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?</title><secondary-title>Mov Disord</secondary-title></titles><periodical><full-title>Mov Disord</full-title></periodical><dates><year>submitted</year></dates><urls></urls></record></Cite></EndNote>44. The literature research for the 8 non-imaging key questions (Table 1) is reported herein. From the identiﬁed 4166 abstracts, 1035 publications met the criteria for full review. The methodology of 269 articles was considered “very reliable” or “OK”. The evidence pertinent to the diagnosis of PSP for each key question is shown in detail in Supplemental Table 1 and summarized in the following paragraphs. 

Five reliable articles addressed the diagnostic accuracy of the NINDS-SPSP criteria and found them very specific, but not sensitive in the early clinical course ADDIN EN.CITE ,. Alternative clinical diagnostic criteria were not better for early diagnosis ADDIN EN.CITE ,. Major challenges are the absence of features specific for PSP-RS, particularly ocular motor dysfunction, in some patients with PSP, and the clinical overlap with other diseases (particularly PD, MSA-P, CBD, and FTD).

Two large clinico-pathological series of PSP patients identified 3 coherent clusters of symptoms by hypothesis-free cluster analysis ADDIN EN.CITE ,. These were 1) supranuclear gaze palsy and falls, 2) parkinsonian signs/symptoms, and 3) cognitive symptoms. We considered these functional domains most relevant to the clinical manifestation of definite PSP.

The literature from the past 20 years emphasizes vPSP syndromes other than PSP-RS: definite PSP patients were reported in small series with initial predominance of ocular motor dysfunction (PSP-OM) ADDIN EN.CITE 4, postural instability (PSP-PI) ADDIN EN.CITE ,, parkinsonism resembling idiopathic Parkinson’s disease (PSP-P) ADDIN EN.CITE ,, frontal lobe cognitive or behavioral presentations (PSP-F) ADDIN EN.CITE ,,, progressive gait freezing (PSP-PGF) ADDIN EN.CITE ,,,, speech/language disorders (PSP-SL) including non-fluent/agrammatic variant of primary progressive aphasia (nfaPPA) ADDIN EN.CITE ,, and progressive apraxia of speech (AOS) ADDIN EN.CITE ,, corticobasal syndrome (PSP-CBS) ADDIN EN.CITE ,,, primary lateral sclerosis (PSP-PLS) ADDIN EN.CITE 32, or cerebellar ataxia (PSP-C) ADDIN EN.CITE ,.

A broad spectrum of diseases other than PSP have been clinically reported to present similarly to PSP (PSP look-alikes) and need to be considered in the differential diagnosis (Supplemental Table 1).

Available studies on neuropsychological testing are limited by lack of autopsy confirmation and the inclusion of mostly PSP-RS cases. The few studies with autopsy-confirmation revealed that PSP may present with features classically attributed to FTD, such as bvFTD ADDIN EN.CITE ,, and nfaPPA HYPERLINK \l "_ENREF_31" \o "Mochizuki, 2003 #10"  ADDIN EN.CITE <EndNote><Cite><Author>Mochizuki</Author><Year>2003</Year><RecNum>11</RecNum><DisplayText><style face="superscript">31</style></DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="9wtt2ede7xfea6eae9dpde50vp0s2f0d0rtf" timestamp="1480348608">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mochizuki, A.</author><author>Ueda, Y.</author><author>Komatsuzaki, Y.</author><author>Tsuchiya, K.</author><author>Arai, T.</author><author>Shoji, S.</author></authors></contributors><auth-address>Department of Neurology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Ibaraki, Japan. mochiza@md.tsukuba.ac.jp</auth-address><titles><title>Progressive supranuclear palsy presenting with primary progressive aphasia--clinicopathological report of an autopsy case</title><secondary-title>Acta Neuropathol</secondary-title></titles><pages>610-4</pages><volume>105</volume><number>6</number><keywords><keyword>Aged</keyword><keyword>Aging/metabolism/pathology</keyword><keyword>Aphasia, Primary Progressive/*complications/pathology</keyword><keyword>Autopsy</keyword><keyword>Blotting, Western</keyword><keyword>Brain/anatomy &amp; histology/metabolism</keyword><keyword>Disease Progression</keyword><keyword>Humans</keyword><keyword>Immunohistochemistry</keyword><keyword>Magnetic Resonance Imaging</keyword><keyword>Male</keyword><keyword>Neurofibrillary Tangles/metabolism/pathology</keyword><keyword>Protein Isoforms/immunology/metabolism</keyword><keyword>Supranuclear Palsy, Progressive/*complications/pathology</keyword><keyword>tau Proteins/metabolism</keyword></keywords><dates><year>2003</year><pub-dates><date>Jun</date></pub-dates></dates><isbn>0001-6322 (Print)&#xD;0001-6322 (Linking)</isbn><accession-num>12669238</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/12669238</url></related-urls></urls><electronic-resource-num>10.1007/s00401-003-0682-5</electronic-resource-num></record></Cite></EndNote>31. The typical frontal syndrome of PSP appears to comprise apathy, bradyphrenia (i.e., slowness of thinking), executive dysfunction, reduced phonemic verbal fluency, impulsivity, disinhibition, and perseveration ADDIN EN.CITE 52-56. 
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The literature on genetics of PSP confirms that PSP is generally sporadic. However, non-Mendelian family histories for neurodegenerative diseases were found in up to 33% of PSP index patients ADDIN EN.CITE ,. Homozygosity for the H1 haplotype of MAPT and polymorphisms at STX6, MOBP and EIF2AK3 represent risk factors for sporadic PSP ADDIN EN.CITE 68. Mendelian inheritance of PSP-like syndromes occurs rarely due to MAPT mutations ADDIN EN.CITE , but the similarity to PSP-RS is only partial. Mutations in other genes can present as syndromes with similarity to PSP, but they have either no or an uncertain relationship to definite PSP (Supplemental Table 1). 

Studies on fluid biomarkers in PSP lack of sufficient sample numbers, homogeneity (clinical phenotype, co-morbidities, co-medication, etc.), and autopsy-confirmation, but also suffer technical shortcomings (heterogeneous sample processing, assay limitations, lack of independent confirmation). It is established, however, that the CSF concentrations of total and phosphorylated tau are not increased in PSP patients, unlike in Alzheimer’s disease (AD) ADDIN EN.CITE 71.

Clinico-pathological case series
Detailed clinical data were available for autopsy confirmed cases of PSP (N=206), CBD (N=54), MSA-P (N=51), PD (N=53), and FTLD-bvFTD (N=73). Characteristics of 100/206 PSP patients have been described previously ADDIN EN.CITE 4. A subset of control patients (CBD, MSA-P, PD, FTLD-bvFTD) have been published previously in disease-specific studies but not in systematic comparative evaluations of PSP features. Their demographic data, as shown in Table 2, are consistent with previously published data ADDIN EN.CITE ,. No PSP patient had a symptom onset prior to 41 years of age, nor a Mendelian inheritance pattern or a known MAPT mutation. The FTLD cases had varying pathology (75% TDP-43, 21% Tau (other than PSP or CBD), 4% FUS); 34% (N=25) were hereditary, 5% (N=4) with MAPT mutations, 29% (N=21) with known mutations other than MAPT; 23% (N=17) were associated with motor neuron disease. 

Table 3 lists the diagnoses made at the initial and final ante mortem clinical evaluation. For 122 (59%) and 182 (88%) of 206 PSP patients, the initial and final diagnoses were recorded, respectively. PSP was correctly diagnosed in 31 of 122 cases (25%) initially and in 114 of 182 patients (63%) at final visit. PD was the most common clinical misdiagnosis in PSP patients [28/122 (23%) initially, 18/182 (10%) at final visit].

The frequency of 37 clinical features throughout the disease course is shown in Supplemental Table 3. Based on the literature review we selected symptoms of putative diagnostic value and calculated their sensitivity, PPV, and specificity in our clinico-pathological cohort (Table 4).

Ocular motor dysfunction
The presence of vertical supranuclear gaze palsy throughout the disease had a specificity of 91% for definite PSP, increasing to 97% when present within the first 3 years after disease onset; sensitivity was 71% throughout, but only 30% in the first 3 years. Because the retrospective analysis did not provide reliable data on slowing of saccades for many patients, the term was generalized to abnormal saccades. These were recorded in 66% of PSP patients throughout the disease, yielding a specificity of 85%. When present within the first 3 years, sensitivity for PSP decreased to 31% but specificity increased to 94%. Non-specific ocular symptoms (defined as any of painful eyes, dry eyes, visual blurring, diplopia, blepharospasm, ptosis, reduced blinking rate, or “apraxia of eyelid opening”) were recorded in 36% of PSP patients throughout the disease, but only 2-11% in control groups, yielding a high specificity (94%).

Postural instability 
Postural instability throughout the disease course was the most frequent symptom in PSP (82%), but had low specificity (46%), also being common in CBD, MSA-P and PD. Postural instability within the first 3 years was observed in only 54% of PSP patients, but had considerably better specificity (81%). Postural instability within the first year had even higher specificity (90%), but lower sensitivity (45%).
Falls throughout the disease course had moderate sensitivity (79%) and specificity (59%) for PSP. Falls in the first 3 years had reduced sensitivity (51%), but improved specificity (86%). Falls in the first year resulted in even lower sensitivity (37%) and only slightly improved specificity (94%). 

Akinesia and gait freezing
Akinetic-rigid, predominantly axial, and levodopa-resistant parkinsonism distinguished PSP with a sensitivity of only 29% and specificity of 92%. Parkinsonism with tremor and/or asymmetry and/or levodopa-responsiveness identified PSP with higher sensitivity (44%) but lower specificity (47%). The most specific symptom for PSP (100%) was progressive gait freezing within the first 3 years, defined as gait freezing or start hesitation in the absence of limb rigidity, tremor, or dementia and without response to levodopa HYPERLINK \l "_ENREF_34" \o "Williams, 2007 #1"  ADDIN EN.CITE <EndNote><Cite><Author>Williams</Author><Year>2007</Year><RecNum>1</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="vvde5fa9f2a0x6etsdov2swo0ravvap0w5ef" timestamp="1481191109">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Williams, D. R.</author><author>Holton, J. L.</author><author>Strand, K.</author><author>Revesz, T.</author><author>Lees, A. J.</author></authors></contributors><auth-address>Faculty of Medicine (Neurosciences), Monash University (Alfred Hospital Campus), Melbourne, Australia. david.williams@med.monash.edu.au</auth-address><titles><title>Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy</title><secondary-title>Mov Disord</secondary-title></titles><pages>2235-41</pages><volume>22</volume><number>15</number><keywords><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Brain/metabolism/pathology</keyword><keyword>Fatal Outcome</keyword><keyword>Female</keyword><keyword>Gait Disorders, Neurologic/classification/*pathology/*physiopathology</keyword><keyword>Humans</keyword><keyword>Immunohistochemistry</keyword><keyword>Lewy Bodies/pathology</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Movement Disorders/classification/*pathology/*physiopathology</keyword><keyword>Phenotype</keyword><keyword>Retrospective Studies</keyword><keyword>Supranuclear Palsy, Progressive/classification/*pathology/*physiopathology</keyword><keyword>alpha-Synuclein/metabolism</keyword></keywords><dates><year>2007</year><pub-dates><date>Nov 15</date></pub-dates></dates><isbn>0885-3185 (Print)&#xD;0885-3185 (Linking)</isbn><accession-num>17712855</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/17712855</url></related-urls></urls><electronic-resource-num>10.1002/mds.21698</electronic-resource-num></record></Cite></EndNote>34; however it was only present in very few PSP patients (2%). 

Cognitive dysfunction
Non-fluent/agrammatic primary progressive aphasia (nfaPPA) was present in 19% of definite PSP cases. nfaPPA also occurred in FTLD-bvFTD (16%) and in CBD (28%). Specificity of nfaPPA for PSP in our cohort was 88%. When noted in the first 3 years, nfaPPA had lower sensitivity (9%), but higher specificity (91%) for PSP. Apraxia of speech (AOS) had low sensitivity (4%) but high specificity (94%) for PSP. When considering AOS in the first 3 years only, sensitivity was even lower (1%) and specificity higher (97%). However, it should be noted that only cases of FTLD-bvFTD patients were included in our study and thus, including FTLD-PPA cases could have reduced the specificity of these findings for PSP. 
Frontal dysfunction was defined as the presence of at least 1 of the following: personality change, frontal behavior, social dysfunction, executive dysfunction, and frontal physical signs. Information on the type of frontal dysfunction was too limited for differential analysis. Presence of frontal dysfunction throughout the course had a sensitivity for PSP of 57% and a specificity of 46%. When present within the first 3 years, sensitivity was only 30% and specificity was 63%.
Corticobasal syndrome (CBS), defined as at least one cortical and one movement disorder sign ADDIN EN.CITE 76 occurred in 13% of our PSP cases, yielding a specificity of 93% for PSP. As expected, CBD was the most relevant differential diagnosis. 

Other features
Dysarthria and dysphagia throughout the disease course had limited specificity for PSP (54% and 55%, respectively). Specificity increased markedly for both symptoms if these were present within the first 3 years of disease (84% and 87%, respectively).
Ten PSP cases (5%) and 55 control cases (24%) had clinical features considered to be supportive for diagnoses other than PSP. These were 1) impairment of episodic memory within the first year of disease, suggestive of AD (3 PSP, 8 CBD, 2 PD, 1 FTLD), 2) unexplained autonomic failure within the first year of disease, suggestive of MSA (5 PSP, 10 MSA-P, 1 PD, 1 CBD), 3) unexplained visual hallucinations within the first year of disease, suggestive of dementia with Lewy bodies (1 PSP), 4) unexplained multisegmental upper and lower motor neuron signs, suggestive of motor neuron disease (17 FTLD), 5) appendicular ataxia (1 PSP, 2 MSA-P), and 6) hereditary cases with mutations other than MAPT (21 FTLD). 

Discussion 
Here we sought to identify the ante-mortem clinical features that individually predict PSP pathology, by analyzing retrospective clinical data from a large autopsy cohort of PSP, CBD, MSA-P, PD and FTLD patients. For the same purpose, we conducted an extensive systematic literature review on features relevant for the diagnosis of PSP, published since 1996. The need for this work is apparent from the low rate of correct clinical diagnoses observed in this very cohort. Clinical diagnosis of PSP was correct in only 25% of the cases at first visit, and in 63% at last visit, highlighting that PSP is underdiagnosed. One of the reasons for clinical underdiagnosis of pathologically defined PSP is its phenotypic variability ADDIN EN.CITE ,. In vPSP syndromes other than PSP-RS, characteristic key features may be missing, especially early in the disease course. Indeed, 33% of the PSP patients reported here never developed supranuclear gaze palsy, and 23% did not have postural instability and falls, similar to observations from previous studies ADDIN EN.CITE ,,,,. This explains why the NINDS-SPSP clinical diagnostic criteria for PSP have suboptimal sensitivity, as confirmed in our literature review ADDIN EN.CITE 9-11. The results of this study should serve as a framework to develop new clinical diagnostic criteria for PSP.

The results from the autopsy cohort showed that the key features of PSP-RS are highly specific for PSP pathology. Vertical supranuclear gaze palsy, abnormal saccades, postural instability, and falls were highly specific for PSP, in agreement with previous reports ADDIN EN.CITE ,, Notably, CBS was also very specific for PSP (93%). A limited specificity of CBS for CBD was reported previously HYPERLINK \l "_ENREF_26" \o "Ling, 2010 #293"  ADDIN EN.CITE <EndNote><Cite><Author>Ling</Author><Year>2010</Year><RecNum>293</RecNum><DisplayText><style face="superscript">26</style></DisplayText><record><rec-number>293</rec-number><foreign-keys><key app="EN" db-id="wxrax9w07529swefspux0dz1psdvwvr0evwx" timestamp="1480238435">293</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ling, H.</author><author>O&apos;Sullivan, S. S.</author><author>Holton, J. L.</author><author>Revesz, T.</author><author>Massey, L. A.</author><author>Williams, D. R.</author><author>Paviour, D. C.</author><author>Lees, A. J.</author></authors></contributors><auth-address>Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, 1 Wakefield Street, London WC1N 1PJ, UK.</auth-address><titles><title>Does corticobasal degeneration exist? A clinicopathological re-evaluation</title><secondary-title>Brain</secondary-title></titles><periodical><full-title>Brain</full-title></periodical><pages>2045-57</pages><volume>133</volume><number>Pt 7</number><keywords><keyword>Aged</keyword><keyword>Aged, 80 and over</keyword><keyword>Basal Ganglia/*pathology</keyword><keyword>Basal Ganglia Diseases/classification/pathology</keyword><keyword>Cerebral Cortex/*pathology</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Neurodegenerative Diseases/*classification/*pathology</keyword><keyword>Retrospective Studies</keyword><keyword>Supranuclear Palsy, Progressive/classification/pathology</keyword></keywords><dates><year>2010</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>1460-2156 (Electronic)&#xD;0006-8950 (Linking)</isbn><accession-num>20584946</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/20584946</url></related-urls></urls><electronic-resource-num>10.1093/brain/awq123</electronic-resource-num></record></Cite></EndNote>26. In light of this data, it is difficult to maintain the concept of CBS as the hallmark of CBD. Other features with high specificity for PSP included progressive gait freezing within the first 3 years (100% specificity) ADDIN EN.CITE ,, as well as AOS and nfaPPA ADDIN EN.CITE ,,. However, only FTLD-bvFTD was included in our cohort and the addition of cases with FTLD-PPA would have reduced the specificity of PPA features for PSP. Interestingly, predominantly axial and levodopa-resistant parkinsonism, a feature not mentioned in the NINDS-SPSP criteria, was reasonably specific for PSP pathology. Thus, to diagnose PSP with high specificity, the aforementioned features should be considered when designing new criteria.

One of the major shortcomings of the NINDS-SPSP criteria is low sensitivity ADDIN EN.CITE 9-11. With regard to the key features of PSP-RS, expanding the time window for onset of postural instability and falls from the first year (as required in the NINDS-SPSP criteria) to the first 3 years after disease onset resulted in improved sensitivity for a diagnosis of PSP (falls: from 37 to 51%; postural instability: from 45 to 54%). Similarly, the presence of frontal dysfunction, dysarthria and/or dysphagia, and parkinsonism with tremor and/or asymmetry and/or levodopa-response had good sensitivity; however, the specificity of these findings for PSP was, as expected, limited. Frontal dysfunction was also common in CBD and bvFTD, and dysphagia and dysarthria were frequently present in MSA-P and bvFTD, often early in the disease course. In summary, the results of this cohort study show that 1) there are a variety of features that may be acknowledged in order to increase sensitivity of diagnosing PSP, and 2) not unexpectedly, this increase in sensitivity comes at the expense of specificity. 

Ideally, diagnostic investigations should be added to the clinical diagnostic criteria of PSP to increase both specificity and sensitivity. However, our literature review highlights the lack of any in vivo investigation that reliably predicts PSP pathology and might be useful for the clinical diagnostic criteria. While autopsy confirmation was available in a reasonable number of retrospective studies that reported on the natural history of PSP, it was missing in most studies related to additional diagnostic investigations, including autonomic testing, neuropsychological testing, oculomotor analysis, and biomarker assessments. In these studies, only PSP-RS patients were evaluated, and the use/extent of additional diagnostic investigations in a more challenging diagnostic context is unclear. For diagnostic imaging in PSP we refer to a comprehensive review of the MDS-PSPSG reported in detail in an accompanying paper HYPERLINK \l "_ENREF_44" \o "Whitwell, submitted #1121"  ADDIN EN.CITE <EndNote><Cite><Author>Whitwell</Author><Year>submitted</Year><RecNum>1121</RecNum><DisplayText><style face="superscript">44</style></DisplayText><record><rec-number>1121</rec-number><foreign-keys><key app="EN" db-id="wxrax9w07529swefspux0dz1psdvwvr0evwx" timestamp="1483988833">1121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Whitwell</author></authors></contributors><titles><title>Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?</title><secondary-title>Mov Disord</secondary-title></titles><periodical><full-title>Mov Disord</full-title></periodical><dates><year>submitted</year></dates><urls></urls></record></Cite></EndNote>44. With regard to genetic testing, homozygosity for the MAPT H1 haplotype polymorphism is frequent in, but not diagnostic for PSP. Homozygosity for the MAPT H2 haplotype polymorphism is very rare in PSP, but does not exclude the diagnosis. Rare MAPT mutations can cause a PSP-like presentation, albeit obviously with a distinct etiology than the sporadic disease. However, genetic testing, as well as CSF biomarkers, can be helpful to identify PSP look-alikes, including prion disease, hereditary spinocerebellar ataxias, Perry syndrome, Kufor-Rakeb disease, Whipple´s disease, Niemann-Pick disease type C, Gaucher’s disease, progressive encephalomyelitis with rigidity and myoclonus, and AD. AD rarely presents clinically as PSP-RS or levodopa-resistant parkinsonism, but can clinically mimic other PSP-phenotypes, most notably CBS (in up to 25% of cases), but also nfaPPA and bvFTD; thus AD biomarkers (CSF Aβ and tau, amyloid PET) may be indicative of primary AD pathology in these syndromes. Research should be encouraged to identify investigations useful for the early clinical diagnosis of PSP, as is the case in other neurodegenerative disorders such as AD ADDIN EN.CITE 77. It remains to be seen whether tau-PET imaging will qualify as a useful ancillary test.

Lastly, we were unable to identify specific features that could convincingly describe a characteristic prodromal phase of PSP, although individual reports clearly described speech/language, behavioral, or cognitive features as pre-motor manifestations in patients diagnosed with PSP upon follow-up or autopsy. Early clinical features of PSP are yet poorly addressed in the literature. It will be crucial to prospectively study putative PSP patients presenting with non-specific, albeit suggestive features in a prospective setting, starting at the earliest clinical stages of the disease course. 

There are several limitations of our work. Data were obtained from clinical charts and may be incomplete, as in any retrospective clinico-pathological study. The numbers of cases per diagnosis did not present relative frequencies expected in the general population. To our knowledge, the only community-based autopsy series focusing on pathologically defined diseases of interest for our study, found the following relative frequencies in 233 autopsy cases: 19% PD, 13% TDP-43 proteinopathy, 3% PSP (including anatomically restricted forms), 0.9% PSP sensu stricto, 0.9% MSA, and 0.4% CBD ADDIN EN.CITE 78. Any approach to mimic the population-based prevalence of diseases would have required introducing a massive distortion of the brain bank frequencies. Hence, the relatively low numbers of PD cases included in this cohort introduces a bias that needs to be recognized when interpreting PPV and specificity. A selection bias over-representing cases with unusual clinical features cannot be excluded either. Thus PPV and specificity of clinical features for PSP might be underestimated in this cohort. The presence of some features, such as slowing of vertical saccades, may not have been documented, or missed entirely. However, the presented data was extracted from the largest clinico-pathological cohort of PSP published to date, and compared with a substantial number of pathologically confirmed patients with the most relevant differential diagnoses. In future, multivariate statistical models may increase diagnostic accuracy by considering clinical variables jointly, rather than singly, but such models are less easy to apply in the clinical setting.

In conclusion, our work provides a strong rationale for developing new diagnostic criteria for PSP. The various phenotypes and symptoms from 4 functional domains (“ocular motor dysfunction”, “postural instability”, “akinesia”, “cognitive dysfunction”), with characteristic clinical features each, should be considered when conceptualizing new criteria. Different levels of diagnostic certainty will need to be implemented into the criteria to allow for inclusion of symptoms with differing sensitivity and specificity, including features which are non-specific, but relevant for early and sensitive diagnosis of PSP.
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